AR057890A1 - Inhibidores de la proteasa aspartica - Google Patents
Inhibidores de la proteasa asparticaInfo
- Publication number
- AR057890A1 AR057890A1 ARP060104967A ARP060104967A AR057890A1 AR 057890 A1 AR057890 A1 AR 057890A1 AR P060104967 A ARP060104967 A AR P060104967A AR P060104967 A ARP060104967 A AR P060104967A AR 057890 A1 AR057890 A1 AR 057890A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nhc
- cycloalkylalkyl
- nhr9
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invencion se refiere a inhibidores de la proteasa aspártica. Reivindicacion 1: Un compuesto representado por la siguiente formula estructural (1); o una sal farmacéuticamente aceptable del mismo, en el que: Z es -O- o -CH2-. X1 es un enlace covalente, -O-, -S-, -S(O)-, -S(O)2-. Y1 es un enlace covalente o alquileno C1-10, alquenileno C1-10 o alquinileno C1-10, cada uno opcionalmente sustituido en uno o más átomos de carbono sustituibles con halogeno, ciano, hidroxilo, alquilo (C1-3), alcoxi (C1-3) o haloalcoxi (C1-3), con la condicion de que Y1 sea un enlace covalente solo cuando X1 es un enlace covalente. R1 es a) cicloalquilo (C3-7); o b) fenilo, heteroarilo o heteroarilo bíciclico opcionalmente sustituido con 1 a 3 grupos seleccionados opcionalmente entre: 1) fluor, cloro, bromo, ciano, nitro, alquilo (C1-6), cicloalquilo (C3-6), cicloalquilalquilo (C4-7), alquenilo (C2-6), cicloalquilalquenilo (C5-7), alquinilo (C2-6), cicloalquil (C3-6)-alquinilo (C2-4), haloalquilo (C1-6), halocicloalquilo (C3-6), halocicloalquilalquilo (C4-7), haloalquenilo (C2-6), haloalquinilo (C3-6), halocicloalquilalquinilo (C5-7), alcoxi (C1-6), cicloalcoxi (C3-6), cicloalquilalcoxi (C4-7), haloalcoxi (C1-6), halocicloalcoxi (C3-6), halocicloalquilalcoxi (C4-7) y alcanosulfonilo (C1-6); o 2) fenilo, heteroarilo, fenixo, heteroariloxi, feniltio, heteroariltio, bencilo, heteroarilmetilo, benciloxi y heteroarilmetoxi, cada uno opcionalmente sustituido con 1 a 3 con grupos seleccionados independientemente entre: fluor, cloro, ciano, alquilo (C1-3), haloalquilo (C1-3), alcoxi (C1-3), haloalcoxi (C1-3) y aminocarbonilo. R2 es -OC(O)(NH2), -OC(S)(NH2), -SC(S)(NH2), -SC(O)(NH2), -OC(O)(NHR9), -OC(S)(NHR9), -SC(S)(NHR9), - SC(O)(NHR9), -NHC(O)OR9, -NHC(S)SR9, -NHC(S)OR9, -NHC(O)SR9, -C(O)R9, -C(S)R9, -C(O)(NH2), C(S)(NH2), -C(O)(NHR9), -C(S)(NHR9) o -NHC(O)H, donde R9 es un alquilo C1-5 lineal o ramificado, haloalquilo C1-5 lineal o ramificado, cicloalquilo (C3-4) o alcoxialquilo C1-5 lineal o ramificado. R3 es -H, -F, alquilo C1-5, -NHC(O)R10, -OH o -OR10, donde R10 es alquilo C1-3, con la condicion de que cuando R3 es -F o -OH, entonces X1 no sea -O-, -S-, -S(O)-, -S(O)2- y R1-Y1-X1 no sea -OC(O)(NH2), OC(S)(NH2), -SC(S)(NH2), -SC(O)(NH2), -OC(O)(NHR9), -SC(S)(NHR9), -SC(O)(NHR9), -NHC(O)OR9, -NHC(S)OR9, -NHC(S)SR9, -NHC(O)SR9 o -NHC(O)H. Q es un resto seleccionado del grupo de formulas (2) en los que N y N están unidos a los enlaces truncados. R4 es -H o alquilo (C1-3). R5 y R6 son independientemente a) H, alquilo (C1-10), cicloalquilalquilo (C4-10), haloalquilo (C1-10, hidroxialquilo (C1-10), halocicloalquilalquilo (C4-10), cicloalquilalquilo (C4-10) hidroxilado, alquil (C1-2)- cicloalquilalquilo C4-10), alquil (C1-2)-cicloalquilalquilo (C4-10) halogenado, dialquil (C1-2)-cicloalquilalquilo (C4-10), alquil (C1-2)-cicloalquilalquilo (C4-10) hidroxilado, dialquil (C1-2)-cicloalquilalquilo (C4-10) hidroxilado, bicicloalquil (C4-10)- alquilo (C1-3), tricicloalquil (C8-12)-alquilo (C1-3), alcoxialquil (C1-5)-alquilo (C1-5), haloalcoxi (C1-5)-alquilo (C1-5), alquiltio (C1-5)-alquilo (C1-5), haloalquiltio (C1-5)-alquilo (C1-5) o heterociclilalquilo (C1-3) saturado; o b) fenilalquilo (C1-2), fenoximetilo o heteroarilalquilo (C1-2) cada uno opcionalmente sustituido con 1 a 3 grupos seleccionados independientemente entre fluor, cloro, ciano, alquilo (C1-3), haloalquilo (C1-3), alcoxi (C1-3) y haloalcoxi (C1-3), con la condicion de que R5 y R6 no sean los dos H; G es OH, NH2 o NHR7. R7 es a) -alquilo (C1-6), haloalquilo (C1-6), cicloalquilalquilo (C4-10), alcoxi (C1-5)-alquilo (C1-5) o aminocarbonialquilo (C1-6) o b) fenilalquilo (C1-2) opcionalmente sustituido con 1 a 3 grupos seleccionados independientemente entre: fluor, cloro, ciano, alquilo (C1-3), haloalquilo (C1-3), alcoxi (C1-3) y haloalcoxi (C1-3); o c) R5 y R7 juntos son -CH2-, -(CH2)2-, -(CH2)3- O -(CH2)4-, opcionalmente sustituidos con 1 o 2 grupos seleccionados independientemente entre fluor, alquilo (C1-8), haloalquilo (C1-8), cicloalquilo (C3-6), halocicloalquilo (C3-6), hidroxicicloalquilo (C3-6), cicloalquil (C3-6)-alquilo (C1-2), halocicloalquil (C3-6)-alquilo (C1-2), cicloalquil (C3-6)-alquilo (C1-2) hidroxilado, alcoxi C1-8), haloalcoxi (C1-8), cicloalcoxi (C3-6), halocicloalcoxi (C3-6) y heterociclilo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73656405P | 2005-11-14 | 2005-11-14 | |
US84533106P | 2006-09-18 | 2006-09-18 | |
US84529106P | 2006-09-18 | 2006-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057890A1 true AR057890A1 (es) | 2007-12-26 |
Family
ID=37812974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104967A AR057890A1 (es) | 2005-11-14 | 2006-11-14 | Inhibidores de la proteasa aspartica |
Country Status (16)
Country | Link |
---|---|
US (1) | US8487108B2 (es) |
EP (1) | EP1966139B1 (es) |
JP (1) | JP2009515893A (es) |
KR (1) | KR101379663B1 (es) |
AR (1) | AR057890A1 (es) |
AT (1) | ATE538092T1 (es) |
AU (1) | AU2006325322B2 (es) |
BR (1) | BRPI0618585A2 (es) |
CA (1) | CA2628952C (es) |
HK (1) | HK1121459A1 (es) |
NO (1) | NO20082108L (es) |
NZ (1) | NZ568042A (es) |
PE (2) | PE20070804A1 (es) |
SG (1) | SG169983A1 (es) |
TW (1) | TWI411607B (es) |
WO (1) | WO2007070201A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101072561B (zh) | 2004-10-07 | 2011-05-11 | 生命医药公司 | 二氨基烷烃天冬氨酸蛋白酶抑制剂 |
WO2007117560A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Piperidine and morpholine renin inhibitors |
WO2007117482A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
US20090264428A1 (en) * | 2006-04-05 | 2009-10-22 | Baldwin John J | Renin Inhibitors |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
JP2010503682A (ja) * | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ, インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
CL2007002689A1 (es) * | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
US8242290B2 (en) | 2007-09-17 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Process for the preparation of renin inhibitors |
WO2009038715A1 (en) * | 2007-09-17 | 2009-03-26 | Vitae Pharmaceuticals, Inc. | Process for the preparation of renin inhibitors |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
WO2009158377A1 (en) * | 2008-06-26 | 2009-12-30 | Smith Kline Beecham Corporation | Salts of methyl 2-((r))-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate |
US20100010228A1 (en) * | 2008-06-26 | 2010-01-14 | Vitae Pharmaceuticals, Inc. | Process for the asymmetric reduction of 3-benzoylpiperidines |
MY153606A (en) | 2008-08-05 | 2015-02-27 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-one derivatives |
WO2010111634A2 (en) * | 2009-03-26 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
JP5616977B2 (ja) * | 2010-12-15 | 2014-10-29 | 国立大学法人北海道大学 | 光学活性アルコール化合物の製造方法 |
WO2012081582A1 (ja) * | 2010-12-15 | 2012-06-21 | 国立大学法人北海道大学 | ジアステレオ選択的にアルコール化合物を製造する方法及びルテニウム化合物 |
CA2882038A1 (en) | 2012-08-16 | 2014-02-20 | Janssen Pharmaceutica Nv | Substituted pyrazoles as n-type calcium channel blockers |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
WO2023217989A1 (en) | 2022-05-12 | 2023-11-16 | Syngenta Crop Protection Ag | Alkoxy heteroaryl- carboxamide or thioamide compounds |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
WO2024126650A1 (en) | 2022-12-15 | 2024-06-20 | Syngenta Crop Protection Ag | Novel bicyclic-carboxamide compounds useful as pesticides |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3071618A (en) * | 1956-02-02 | 1963-01-01 | Pfizer & Co C | Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines |
US4136163A (en) * | 1971-02-04 | 1979-01-23 | Wilkinson Sword Limited | P-menthane carboxamides having a physiological cooling effect |
GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
JPS5115098A (ja) | 1974-07-26 | 1976-02-06 | Asahi Chemical Ind | Akurirukeiseniseihinno shorihoho |
US4594343A (en) | 1984-10-19 | 1986-06-10 | Shanklin Jr James R | 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles |
GB8810067D0 (en) | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
US4908372A (en) * | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
DE4018070A1 (de) * | 1990-06-06 | 1991-12-12 | Bayer Ag | Morpholinoharnstoff-derivate |
JP3112290B2 (ja) * | 1990-12-14 | 2000-11-27 | メレルダウファーマスーティカルズ インコーポレイテッド | 抗アレルギー化合物 |
PT626968E (pt) * | 1992-02-13 | 2002-03-28 | Merrell Pharma Inc | Derivados de piperidinilo tiaciclicos |
EP0773921B1 (en) | 1994-07-29 | 1999-12-01 | Abbott Laboratories | Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane |
US5767144A (en) * | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
US6162927A (en) * | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
EP0983269A4 (en) | 1997-05-29 | 2001-06-27 | Lilly Co Eli | PROCESSES USEFUL FOR THE PREPARATION OF HETEROCYCLIC COMPOUNDS |
WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
GB9826540D0 (en) * | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
US6613764B1 (en) | 1999-01-06 | 2003-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Aspartic protease inhibitors |
JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | N−置換ピペリジン誘導体 |
CN1416346A (zh) * | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
US6900329B2 (en) * | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
BR0211119A (pt) | 2001-07-11 | 2005-12-13 | Elan Pharm Inc | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto |
MXPA04004428A (es) * | 2001-11-08 | 2004-09-10 | Elan Pharm Inc | Derivados de 2,3-diamino-2-hidroxipropano n,n`-sustituidos. |
TWI332956B (en) | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
WO2004002483A1 (en) * | 2002-06-27 | 2004-01-08 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease |
US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
MXPA05002705A (es) | 2002-09-10 | 2005-09-08 | Pharmacia & Upjohn Co Llc | Aminoeteres sustituidos para el tratamiento de la enfermedad de alzheimer. |
ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20070093492A1 (en) * | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
EP1778652A2 (en) | 2004-08-20 | 2007-05-02 | EntreMed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
CN101072561B (zh) * | 2004-10-07 | 2011-05-11 | 生命医药公司 | 二氨基烷烃天冬氨酸蛋白酶抑制剂 |
DK1882684T3 (en) | 2005-05-19 | 2015-01-05 | Astellas Pharma Inc | PYRROLIDE INGREDIENTS OR SALTS THEREOF |
WO2007117560A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Piperidine and morpholine renin inhibitors |
US7872028B2 (en) * | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
JP2010503682A (ja) * | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ, インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
US20100160424A1 (en) * | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
WO2009096996A1 (en) | 2007-06-20 | 2009-08-06 | Smithkline Beecham Corporation | Renin inhibitors |
US7773441B2 (en) * | 2008-06-18 | 2010-08-10 | Micron Technology, Inc. | Memory malfunction prediction system and method |
US20110160300A1 (en) | 2008-06-20 | 2011-06-30 | Marlys Hammond | Renin Inhibitors and Methods of Use Thereof |
WO2009158377A1 (en) | 2008-06-26 | 2009-12-30 | Smith Kline Beecham Corporation | Salts of methyl 2-((r))-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
-
2006
- 2006-10-31 TW TW095140163A patent/TWI411607B/zh not_active IP Right Cessation
- 2006-11-13 NZ NZ568042A patent/NZ568042A/en not_active IP Right Cessation
- 2006-11-13 PE PE2006001432A patent/PE20070804A1/es not_active Application Discontinuation
- 2006-11-13 US US12/084,928 patent/US8487108B2/en not_active Expired - Fee Related
- 2006-11-13 KR KR1020087014407A patent/KR101379663B1/ko not_active IP Right Cessation
- 2006-11-13 AT AT06837406T patent/ATE538092T1/de active
- 2006-11-13 CA CA2628952A patent/CA2628952C/en not_active Expired - Fee Related
- 2006-11-13 EP EP06837406A patent/EP1966139B1/en active Active
- 2006-11-13 WO PCT/US2006/043920 patent/WO2007070201A1/en active Application Filing
- 2006-11-13 AU AU2006325322A patent/AU2006325322B2/en not_active Ceased
- 2006-11-13 BR BRPI0618585-1A patent/BRPI0618585A2/pt not_active IP Right Cessation
- 2006-11-13 JP JP2008540236A patent/JP2009515893A/ja not_active Withdrawn
- 2006-11-13 SG SG201101062-6A patent/SG169983A1/en unknown
- 2006-11-14 AR ARP060104967A patent/AR057890A1/es unknown
-
2008
- 2008-05-07 NO NO20082108A patent/NO20082108L/no not_active Application Discontinuation
-
2009
- 2009-02-23 HK HK09101679.7A patent/HK1121459A1/xx not_active IP Right Cessation
-
2010
- 2010-08-06 PE PE2010000496A patent/PE20120229A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2628952A1 (en) | 2007-06-21 |
PE20070804A1 (es) | 2007-09-06 |
TWI411607B (zh) | 2013-10-11 |
AU2006325322A1 (en) | 2007-06-21 |
HK1121459A1 (en) | 2009-04-24 |
TW200800893A (en) | 2008-01-01 |
US8487108B2 (en) | 2013-07-16 |
ATE538092T1 (de) | 2012-01-15 |
CA2628952C (en) | 2014-04-01 |
JP2009515893A (ja) | 2009-04-16 |
SG169983A1 (en) | 2011-04-29 |
BRPI0618585A2 (pt) | 2011-09-27 |
US20100048636A1 (en) | 2010-02-25 |
EP1966139A1 (en) | 2008-09-10 |
PE20120229A1 (es) | 2012-04-04 |
KR20080069685A (ko) | 2008-07-28 |
EP1966139B1 (en) | 2011-12-21 |
NZ568042A (en) | 2010-12-24 |
AU2006325322B2 (en) | 2011-08-04 |
KR101379663B1 (ko) | 2014-04-14 |
WO2007070201A1 (en) | 2007-06-21 |
NO20082108L (no) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057890A1 (es) | Inhibidores de la proteasa aspartica | |
AR046272A1 (es) | Inhibidores de dipeptidil peptidasa iv | |
AR058618A1 (es) | "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa | |
PE20071002A1 (es) | Anticuerpo anti b4-amilode que contiene asparagina glicosilada en la region variable de vh | |
AR072317A1 (es) | Dihidro oxo azinil isoxazolinas herbicidas de seis miembros | |
AR086522A1 (es) | Inhibidores heterociclicos de autotaxina y usos de los mismos | |
PE20200298A1 (es) | Procesos e intermedios para hacer un inhibidor de jak | |
AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
AR069464A1 (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
AR078634A1 (es) | Procedimiento para la preparacion de un polimero organico de silicio foto-protector progresivo; polimero obtenido; su uso para la preparacion de composiciones y como precursor fotoquimico de los absorbentes uv; com-posicion cosmetica o dermatologica que comprende dicho polimero; proce-dimiento para | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR058779A1 (es) | Derivados de tiazol y oxazol como inhibidores de ptp-1b, composiciones farmaceuticas | |
AR041170A1 (es) | Derivados de bencimidazol, benzoxazol y benzotiazol | |
CO5611112A2 (es) | Tripeptidos inhibidores de la hepatitis c con absorcion oral mejorada y composiciones farmaceuticas que los contienen | |
AR056194A1 (es) | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular | |
AR045738A1 (es) | Derivados de bencimidazol n3 alquilados como inhibidores de mek | |
PE20080184A1 (es) | Derivados de aza-biciclo[3.2.1]octan en el tratamiento de diabetes | |
AR081573A1 (es) | N-[(het)ariletil)]pirazo(tio)carboxamidas y sus analogos heterosustituidos y su uso como fungicidas | |
AR067535A1 (es) | Derivados de lactama tetraciclicos | |
AR049140A1 (es) | N-(2-bencil)-2-fenilbutamidas como moduladores del receptor de androgeno | |
AR044476A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
AR060516A1 (es) | Dihidrotienopirimidinas utilizables en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de pde4 y composiciones farmaceuticas que las contienen. | |
CL2011002287A1 (es) | Compuestos derivados de 8-fenoxi-1,1-dioxido-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepina, moduladores de receptores ampa y nmda; composicion farmaceutica; procedimiento de prepapacion; y su uso para tratar enfermedades neurodegenerativas progresivas, alzheimer, parkinson, corea de huntington, entre otras; compuesto intermediario. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |